Does induction treatment increase the risk of morbidity and mortality after pneumonectomy? A multicentre case-matched analysis.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  European Journal of Cardio-Thoracic Surgery

• Publication date

  2010-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejcts.2009.09.018PMID 19836257
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Results of cutting-edge surgery in stage IIIA-N2 nonsmall cell lung cancer

  2009cited by this paper
• INDUCTION AND ADJUVANT THERAPY FOR OPERABLE NON–SMALL CELL LUNG CANCER

  2008cited by this paper
• Risks of neoadjuvant chemotherapy and radiation therapy.

  2008cited by this paper
• Induction chemotherapy does not increase the operative risk of pneumonectomy!

  2007cited by this paper
• Does sleeve lobectomy concomitant with or without pulmonary artery reconstruction (double sleeve) have favorable results for non-small cell lung cancer compared with pneumonectomy? A meta-analysis.

  2007cited by this paper
• Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition).

  2007cited by this paper
• Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition).

  2007cited by this paper
• Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review.

  2007cited by this paper
• Gemcitabine-cisplatin chemotherapy before lung resection: a case-matched analysis of early outcome.

  2006cited by this paper
• Morbidity and mortality in the surgery arm of EORTC 08941 trial

  2005cited by this paper
• Sleeve lobectomy versus pneumonectomy for lung cancer: a comparative analysis of survival and sites or recurrences.

  2004cited by this paper
• Gender and outcomes after coronary artery bypass grafting: a propensity-matched comparison.

  2003cited by this paper
• Comparing apples and oranges.

  2002influential reference
• Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer.

  2002cited by this paper
• Risk factors for early mortality and major complications following pneumonectomy for non-small cell carcinoma of the lung.

  2002cited by this paper
• Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy.

  2001cited by this paper
• Induction chemotherapy increases perioperative complications in patients undergoing resection for non-small cell lung cancer.

  2001cited by this paper
• Postoperative complications in relation with induction therapy for lung cancer.

  2001cited by this paper
• Pneumonectomy for malignant disease: factors affecting early morbidity and mortality.

  2001cited by this paper
• Postoperative complications after combined neoadjuvant treatment of lung cancer.

  1993cited by this paper
• Reducing Bias in Observational Studies Using Subclassification on the Propensity Score

  1984cited by this paper
• The central role of the propensity score in observational studies for causal effects

  1983cited by this paper

• Extended Resections for Lung Cancer.

  2022cites this paper
• Major Pulmonary Resection After Neoadjuvant Therapy in Potentially Resectable Stage IIIA/B Non-Small Cell Lung Carcinoma: R0 or No R0

  2021cites this paper
• Major pulmonary resection after neoadjuvant chemotherapy or chemoradiation in potentially resectable stage III non-small cell lung carcinoma

  2021cites this paper
• Mortality risk factors in lobectomies: Single-institution study

  2019cites this paper
• Use of staplers and adverse events in thoracic surgery.

  2019cites this paper
• [Analysis of postoperative complications after pneumo-n-ectomy using thoracic morbidity and mortality (tmm) system in nsclc patients for a 5-year period].

  2016cites this paper
• Neoadjuvant therapy and risk of bronchopleural fistula after lung cancer surgery: a systematic meta-analysis of 14 912 patients.

  2016cites this paper
• Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection

  2015cites this paper
• Morbidity and mortality after major pulmonary resections in patients with locally advanced stage IIIA non-small cell lung carcinoma who underwent induction therapy.

  2015cites this paper
• A comprehensive treatment approach is necessary for the closure of open window thoracostomy: an institutional review of 35 cases

  2014cites this paper
• Methods of main bronchus stump closure and incidence of bronchopleural fistula after pneumonectomies for lung cancer (a retrospective single center review)

  2014cites this paper
• Neoadjuvant chemotherapy is a risk factor for bronchopleural fistula after pneumonectomy for non-small cell lung cancer

  2014cites this paper
• The role of chemotherapy in the management of stage IIIA non-small cell lung cancer.

  2013cites this paper
• An analysis, systematic review, and meta-analysis of the perioperative mortality after neoadjuvant therapy and pneumonectomy for non-small cell lung cancer.

  2012cites this paper
• Pathological status of mediastinal lymph nodes after preoperative concurrent chemoradiotherapy determines prognosis in patients with non-small cell lung cancer.

  2012cites this paper
• Early complications after lung resections at patients treated for lung cancer with and without Neoadjuvant Hemiotheraphy

  2011cites this paper
• Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer.

  2011cites this paper
• Role of surgery for stage IIIA‐N2 non‐small cell lung cancer

  2011cites this paper
• Pneumonectomy After Induction Therapy for Stage IIIA Non-small-cell Lung Cancer

  2011cites this paper